SEARCH

SEARCH BY CITATION

References

  • Andrew, R., D. G. Watson, S. A. Best, H. Midgey, H. Wenlong & R. K. H. Petty: The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem. Res. 1993, 18, 11751177.
  • Aoki, S., Y. Okada, K. Nishimura, A. J. Barkovich, B. O. Kjos, R. C. Brasch & D. Norman: Normal deposition of brain iron in childhood and adolescence: Magnetic resonance imaging at 1.5 T. Radiology 1989, 172, 381385.
  • Beard, J. L., J. D. Connor & B. C. Jones: Brain iron: location and function. Prog. Food Nutr. Sci. 1993, 17, 183221.
  • Bel, A., E. Martinod & P. Menasche: Cardioprotective effect of desferrioxamine. Acta haematol. 1996, 95, 6365.
  • Ben-Shachar, D., G. Eshel, P. Riederer & M. B. H. Youdim: Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 1992, 32, (Suppl.), S105S110.
  • Ben-Shachar, D., J. P. M. Finberg & M. B. H. Youdim: Effect of iron chelation on dopamine D2 receptors. J. Neurochem. 1985, 45, 9991005.
  • Ben-Shachar, D., E. Livne, I. Spanier, K. L. Leenders & M. B. H. Youdim: Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J. Neurochem 1994, 62, 11121118.
  • Ben-Shachar, D., E. Livne, I. Spanier, R. Zuk & M. B. H. Youdim: Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr. J. Med. Sci. 1993, 29, 587592.
  • Ben-Shachar, D., P. Riederer & M. B. H. Youdim: Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 1991, 57, 16091614.
  • Ben-Shachar D. & M. B. H. Youdim: Selectivity of melanized nigrastriatal dopamine neurons to degeneration in Parlinson's disease may depend on iron-melanin interaction. J. Neural Transm. 1990, 29, (Suppl.) 251258.
  • Ben-Shachar, D. & M. B. H. Youdim: Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J. Neurochem. 1991, 57, 21332135.
  • Benkovic, S. A. & J. R. Connor: Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comparative Neurol. 1993, 338, 97113.
  • Binder, R., J. A. Horowitz, J. P. Basilion, D. M. Koeller, R. D. Klausner & J. B. Harford: Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′ UTR and does not involve poly(A) tail shortening. EMBO J. 1994, 13, 19691980.
  • Blake, D. R., P. Winyard, J. Lunec, A. Williams, P. A. Good, S. J. Crewes, J. M. Gutteridge, D. Rowley, B. Halliwell & A. Cornish: Cerebral and ocular toxicity induced by desferrioxamine. Quart. J. Med. 1985, 56, 345355.
  • Borel, M. J., S. H. Smith, D. E. Brigham & J. L. Beard: The impact of varying degrees of iron nutriture on several functional consequences of iron deficiency in rats. J. Nutr. 1991, 121, 729736.
  • Connor, J. R. & S. A. Benkovic: Iron regulation in the brain: histochemical, biochemical and molecular considerations. Ann. Neurol. 1992, 32, (Suppl.), S51S61.
  • Connor, J. R., B. S. Snyder, P. Arosio, D. A. Loeffler & P. LeWitt: A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 1995, 65, 717724.
  • Connor, J. R., B. S. Snyder, J. L. Beard, R. E. Fine & E. J. Mufson: Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 1992, 31, 327335.
  • Crichton, R. R. & R. J. Ward: Structure and molecular biology of iron binding proteins and the regulation of “free” iron pools. In: Iron and human disease. Ed. R. B.Lauffer CRC Press, Inc., Boca Raton, FL, 1992, pp. 2375.
  • Crowe, A. & E. H. Morgan: Effects of chelators on iron uptake and release by the brain in the rat. Neurochem. Res. 1994, 19, 7176.
  • Dexter, D. T., A. Carayon, F. Javoy-Agid, Y. Agid, F. R. Wells, S. E. Daniel, A. J. Lees, P. Jenner & C. D. Marsden: Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114, 19531975.
  • Dexter, D. T., P. Jenner, A. H. V. Schapira & C. D. Mardsen: Alterations in level of iron, ferritin and other trace metals in neurodegenerative disease affecting basal ganglia. Ann. Neurol. 1992, 32, 94100.
  • Faucheux, B. A., M. T. Herrero, J. Villares, R. Levy, F. Javoy-Agid, J. A. Obeso, J. J. Hauw, Y. Agid & E. C. Hirsch: Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys. Brain Res. 1995a, 691, 115124.
  • Faucheux, B. A., N. Nillesse, P. Damier, G. Spik, A. Mouatt-Prigent, A. Pierce, B. Leveugle, N. Kubis, J. J. Hauw & Y. Agid: Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1995b, 92, 96039607.
  • Galey, J. B., J. Dumats, I. Beck, B. Fernandez & M. Hocquaux: N, N'-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an “oxidative stress activatable” iron chelator in vitro. Free Radic. Res. 1995, 22, 6786.
  • Gerlach, M., D. Ben-Shachar, P. Riederer & M. B. H. Youdim: Altered brain metabolism of iron as a cause of neurodegenerative diseases J. Neurochem. 1994, 63, 793807.
  • Glinka, Y., M. Gassen & M. B. H. Youdim: Iron and neurotransmitter function in brain. In: Metals and oxidative damage in neurological disorders. Ed. J. R.Connors Plenum Publishing Corp, New York, 1996.
  • Glinka, Y., K. F. Tipton & M. B. H. Youdim: Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 1996, 66, 20042010.
  • Gower, J. D., I. J. Ambrose, S. Manek, J. Bright, P. S. Dobbin, R. C. Hider, J. G. Goddard, M. S. Thorniley & C. J. Green: The effect of a synthetic hexadentate iron chelator (CP130) and desferrioxamine on rabbit kidneys exposed to cold and warm ischaemia. Agents Actions 1993, 40, 96105.
  • Hall, E. D. & J. M. McCall: Lazaroids: potent inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. In: Iron in central nervous system disorders. Eds. P.Riederer & M. B. H.Youdim Springer-Verlag, Wien, 1993, pp. 173188.
  • Halliday, J. W. & J. W. Powell: Hereditary hemochromatosis and other diseases associated with iron overload. In: Iron and human disease. Ed. R. B.Lauffer CRC Press, Boca Raton, 1992, pp. 131160.
  • Halliwell, B. & J. M. C. Gutteridge: Oxygen radicals and the nervous system. Trends Neurol. Sci. 1985, 8, 2229.
  • Halliwell, B., J. M. Gutteridge & D. Blake: Metal ions and oxygen radical reactions in human inflammatory joint disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1985, 311, 659671.
  • Harris, L. R., M. H. Cake & D. J. Macey: Iron release from ferritin and its sensitivity to superoxide ions differs among vertebrates. Biochem. J. 1994, 301, 385389.
  • Hasinoff, B. B., S. Venkataram, M. Singh & T. I. Kuschak: Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 1994, 24, 977987.
  • Hermes-Lima, M., R. F. Castilho, A. R. Meinicke & A. E. Vercesi: Characteristics of Fe(II)ATP complex-induced damage to the rat liver mitochondrial membrane. Mol. Cell Biochem. 1995, 145, 5360.
  • Hershko, C.: Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin. Haematol. 1994, 7, 9651000.
  • Hershko, C., G. Link, M. Tzahor & A. Pinson: The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk. Lymphoma 1993, 11, 207214.
  • Hershko, C., A. Pinson & G. Link: Prevention of anthracycline cardiotoxicity by iron chelation. Acta haematol. 1996, 95, 8792.
  • Hider, R. C., R. Choudhury, B. L. Rai, L. S. Dehkordi & S. Singh: Design of orally active iron chelators. Acta haematol. 1996, 95, 612.
  • Jellinger, K., L. Linert, E. Kienzl, E. Herlinger & M. B. Youdim: Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. 1995, 46, (Suppl.) 293310.
  • Kozlov, A. V., A. Bini, D. Gallesi, F. Giovannini, A. Iannone, A. Masini, E. Meletti & A. Tomasi: ‘Free’ iron, as detected by electron paramagnetic resonance spectroscopy, increases unequally in different tissues during dietary iron overload in the rat. Biometals 1996, 9, 98103.
  • Kukielka, E. & A. I. Cederbaum: Ferritin stimulation of hydroxyl radical production by rat liver nuclei. Arch. Biochem. Biophys. 1994, 308, 7077.
  • Leenders, K. L., A. Antonini, R. Schwarzbach, P. Smith-Jones, H. Reist, D. Ben-Shachar, M. Youdim & V. Henn: Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. J. Neural Transm. 1994, 43, (Suppl.) 123132.
  • Lipton, S. A., D. J. Singel & A. Moser: Neuroprotective and neuro-destructive effects of nitric oxide and redox congeners. Ann. N. Y. Acad. Sci. 1994, 738, 382387.
  • Loeffler, D. A., J. R. Connor, P. L. Juneau, B. S. Snyder, L. Kanaley, A. J. DeMaggio, H. Nguyen, C. M. Brickman & P. A. LeWitt: Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 1995, 65, 710724.
  • Martins, E. A., R. L. Robalinho & R. Meneghini: Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake. Arch. Biochem. Biophys. 1995, 316, 128134.
  • Marx, J. J. & B. S. van Asbeck: Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Acta haematol. 1996, 95, 4962.
  • Mash, D. C., J. Pablo, B. E. Buck, J. Sanchez-Ramos & W. J. Weiner: Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp. Neurol. 1991, 114, 7381.
  • Minotti, G. & S. D. Aust: The role of iron in the initiation of lipid peroxidation. Chem. Phys. Lipids 1987, 44, 191208.
  • Morel, I., J. Cillard, G. Lescoat, O. Sergent, N. Pasdeloup, A. Z. Ocaktan, M. A. Abdallah, P. Brissot & P. Cillard: Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic. Biol. Med. 1992, 13, 499508.
  • Morel, I., G. Lescoat, P. Cogrel, O. Sergent, N. Pasdeloup, P. Brissot, P. Cillard & J. Cillard: Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem. Pharmacol. 1993, 45, 1319.
  • Morel, I., O. Sergent, P. Cogrel, G. Lescoat, N. Pasdeloup, P. Brissot, P. Cillard & J. Cillard: EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine. Free Radic. Biol. Med. 1995, 18, 303310.
  • Morris, C. M., J. M. Kerwin & J. A. Edwardson: Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. Neurodegeneration 1994, 3, 267275.
  • Nielsen, J. E., L. N. Jensen & K. Krabbe: Hereditary haemo-chromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J. Neurol. Neurosurg. Psych. 1995, 59, 318321.
  • Olanow, C. W. & M. B. H. Youdim: Iron and neurodegeneration: prospects for neuroprotection. In: Neurodegeneration and neuroprotection in Parkinson's disease. Eds. C. W.Olanow, P.Jenner & M. B. H.Youdim Academic Press, London, 1996, pp. 5567.
  • Olivieri, N. F.: Long-term therapy with deferiprone. Acta haematol. 1996, 95, 3748.
  • Pantopoulos, K. & M. W. Hentze: Nitric oxide signaling to iron regulatory protein: Direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1995a, 92, 12671271.
  • Pantopoulos, K. & M. W. Hentze: Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J. 1995b, 14, 29172924.
  • Riederer, P., A. Dirr, M. Goetz, E. Sofic, K. Jellinger & M. B. H. Youdim: Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 1992, 32, (Suppl.), S101S104.
  • Riederer, P., W. D. Rausch & B. Schmidt: Biochemical fundaments of Parkinson's disease. Mt. Sinai J. Med. 1988, 55, 2129.
  • Riederer, P., E. Sofic, W. D. Rausch, B. Schmidt, G. P. Reynolds, K. Jellinger & M. B. H. Youdim: Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 1989, 52, 512520.
  • Rossi, M. A., M. Curzio, C. DiMauro, F. Fidale, A. Garramone, H. Esterbauer, M. Torrielli & M. U. Dianzani: Experimental studies on the mechanism of action of 4-hydroxy-2,3-trans-non-enal, a lipid peroxidation product displaying chemotactic activity toward rat neutrophils. Cell Biochem. Funct. 1991, 9, 163170.
  • Shoham, S., E. Wertman & R. P. Ebstein: Iron accumulation in the rat basal ganglia after excitatory amino acid injections-dissociation from neuronal loss. Exp. Neurol. 1992, 118, 227241.
  • Siimes, M. A., C. Refino & P. R. Dallman: Manifestation of iron deficiency at various levels of dietary iron intake. Amer. J. Clin. Nutr. 1980, 33, 570574.
  • Singh, V., S. Ahmad & G. S. Rao: Prooxidant and antioxidant properties of iron-hydroquinone and iron-1,2,4-benzenetriol complex. Implications for benzene toxicity. Toxicology 1994, 89, 2533.
  • Sofic, E., W. Paulus, K. Jellinger, P. Riederer & M. B. H. Youdim: Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 1991, 56, 978982.
  • Thomas, L. O., O. B. Boyko, D. C. Anthony & P. C. Burger: MR detection of brain iron. AJNR. Amer. J. Neuroradiol. 1993, 14, 10431048.
  • Trenam, C. W., P. G. Winyard, C. J. Morris & D. R. Blake: Iron promoted oxidative damage in rheumatic diseases. In: Iron and human disease. Ed. R. B.Lauffer CRC Press, Boca Raton, 1992, pp. 395418.
  • van der Wal, N. A., J. F. van Oirschot, A. van Dijk, J. Verhoef & B. S. van Asbeck: Mechanism of protection of alveolar type II cells against paraquat-induced cytotoxicity by desferrioxamine. Biochem. Pharmacol. 1990, 39, 16651671.
  • Xiao, G., D. van der Helm, R. C. Hider & B. L. Rai: Molecular modeling studies of a ferric hexadentate 3-hydroxy-2(1H)-pyridone complex and an analog by molecular mechanics, molecular dynamics, and free energy perturbation simulations. J. Phys. Chem. 1996, 100, 23452352.
  • Yajima, N., H. Hiraishi & T. Harada: Protection of cultured rat gastric cells against oxidant stress by iron chelation. Role of lipid peroxidation. Dig. Dis. Sci. 1995, 40, 879886.
  • Yoritaka, A., N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtman & Y. Mizuno: Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Natl. Acad. Sci. USA 1996, 93, 26962701.
  • Yoshida, T., M. Tanaka, A. Sotomatsu & S. Hirai: Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci. Lett. 1995, 190, 2124.
  • Youdim, M. B. H., D. Ben-Shachar & P. Riederer: Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur. Neurol. 1991, 31, (Suppl.), 3440.
  • Youdim, M. B. H., D. Ben-Shachar & P. Riederer: The possible role of iron in the ethiopathology of Parkinson's disease. Movement Disorders 1993, 8, 112.
  • Youdim, M. B. H., D. Ben-Shachar & P. Riederer: The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm. 1994, 43, (Suppl.) 113122.